Despite the promising results of plerixafor and G-CSF for PBPC mobilization in patients with MM and NHL [3, 4, 6–8], the use of chemotherapy and G-CSF-based regimens to mobilize PBPC remains standard practice in many transplant centers. Here, CSF3 is linked to Miyoshi myopathy.